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EDITORIAL REVIEW
Brain-gut peptides, renal function and cell growth
The history of brain-gut peptides began almost 40 years ago
(longer if you include the discovery of secretin [I]), when
Feyrter [21 described a system of widely distributed gut endo-
crine cells; followed some years later by Pearse's [31 idea that
these cells were derived from the neuroectoderm and could be
grouped according to their common cytochemical characteris-
tics—the acronymous APUD (amine precursor uptake and
decarboxylation) concept. Though not all endocrine cells are
APUD, and many are of endodermal origin, this concept has
been an important stimulus to the discovery of an ever-in-
creasing number of bioactive peptides common to brain and gut
[4]; these are now included under the generic heading of
regulatory peptides [51.
The ubiquity of these peptides, some of their pharmacological
actions, and classification within structurally homologous fam-
ilies, suggest a potential for important physiological effects in
systems other than the gastrointestinal tract, such as, the
cardio-respiratory and immune systems [6—81. Surprisingly little
attention has been given to their possible renal effects. After all,
there is an important embryological link between gut and
kidney; their respective functions in terms of water and elec-
trolyte movement, and cellular transport mechanisms, are often
paralleled.
This review will consider the renal effects of several brain-gut
peptides and their potential for a role in kidney regulation,
including renal cell growth. The renal actions of very few
regulatory neuropeptides have been studied systematically and
observations on several are scattered throughout the biological
literature. We will try to summarize some of these findings,
assess their significance and discuss what aspects (and pep-
tides) might be worth pursuing. We will not discuss the more
"classical" peptide hormones that affect renal function, such
as, parathormone (PTH), arginine vasopressin (AVP), atrial
natriuretic peptide (ANP), and angiotensin II (All), nor the
incidental renal effects of other established hormones, such as
thyroid, sex and pituitary; these have all reviewed extensively
in recent years [9—12]. However, we will consider those neu-
ropeptides that have been implicated in renal cell growth. (In an
effort to restrict the length of this paper, review articles are
often cited rather than original publications).
General comments
Before discussing individual neuropeptides, let us begin by
considering possible modes and mechanisms of action.
Modes of action
As in the gastrointestinal tract, these peptides may reach the
kidney through the circulation as true hormones, or released
locally as neural or paracrine agents [13, 141. Many are vaso-
active and could affect renal transport mechanisms indirectly
through systemic, or local hemodynamic effects; moreover,
changes in intrarenal blood flow could alter access of other
bioactive substances. Indirect effects might also include behav-
ioral changes, specifically altered food and water intake [15],
which in themselves may affect renal function.
Peptides as hormones, Those gut peptides released directly
into the circulation could mediate gut-renal interactions, for
example, glucagon release may be causal in the hyperfiltration
and increased renal blood flow following a protein rich meal [16,
17], as the natriuretic agent responsible for "starvation natri-
uresis" [18], or as the signal for the postulated gut/portal
sodium monitor [19]. The kidney is also an important site of
extraction and metabolism of many peptides, and their circu-
lating pharmacological effects could become significant with
poor renal function [20].
Peptides as neurotransmitters. So far, there has been no
systematic study of the distribution of neuropeptides or their
receptors within the kidney, apart from the early studies of
Hokfelt et al [21], and Barajas [22], where the kidney was
examined by immunocytochemistry as part of a more general
mapping of peptide distribution. With the possible exception of
somatostatin (see later) [23], no peptide-containing cells have
been found in the kidney, excluding any likely paracrine or
autocrine function. This leaves a neurocrine role, which is now
firmly rooted in the identification of peptide- containing nerve
terminals in renal tissue.
Peptidergic innervation of the kidney may have quite dif-
ferent effects when compared with noradrenergic: smaller local
concentrations are apt to have significant cellular actions, and
by virtue of a lack of any known re-uptake mechanism and
dependence upon enzymic degradation, prolonged effects are
more likely [24]. Moreover, the coexistence of several of these
neuropeptides with classical neurotransmitters in brain and
exocrine tissue suggests significant physiological interactions
and a role as important neuromodulators, with feedback within
and between neurons [13, 25]. Another critical difference be-
tween peptides and amine neurotransmitters is the dependence
of the former on protein synthetic mechanisms, and the conse-
quences this may have for regulation of their production and
storage.
Mechanisms of action
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Here, very little is understood, but we can make a start by
considering what is broadly known of hormonal control. Gen-
erally, hormones may act on the kidney through: (1) cytosolic/
nuclear receptor-mediated synthesis of effector proteins (such
as, aldosterone [26]); (2) membrane receptor-G protein-coupled
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Fig. 1. Simplified model of cell signal transduction
via (A) cAMP stimulation, (B) phospholipase C
(PLC) stimulation and phosphoinosito! lipid
breakdown (1P3/1P4). Abbreviations are: R, peptide
hormone receptor; G, 0 protein (stimulatory or
inhibitory); DAG, diacyiglycerol; PKC, protein
kinase C; PKA, protein kinase A; PKB, protein
kinase B. *Only PKC and PKA are thought to be
involved in ion channel regulation [2981. Raised
cytosolic calcium itself may in turn activate
guanylate cyclase [1381 (see substance P 11951).
intracellular cyclic adenosine 3' ,5'-monophosphate (cAMP) ac-
cumulation (the prototypical second messenger, such as, PTH
[27]); (3) phophoinositol metabolism, activation of protein ki-
nase C (PKC) and changes in cytosolic calcium (for example,
angiotensin II [28], Fig. 1). This is an oversimplification, as 0
protein coupling may be inhibitory in (2) [29] and probably (3)
[30]. Moreover, there are complex and important interactions
between (2) and (3) that often appear to be antagonistic [31]. An
additional complication is that peptide hormones may stimulate
more than one mechanism.
So far, much of what is known of peptide hormone regulation
is confined to those peptide hormones able to stimulate a
common pool of adenylate cyclase: PTH, calcitonin, AVP and
glucagon (also beta-adrenergic stimulation). Figure 2 is a sim-
plified and composite diagram of peptide hormone and beta-
adrenergic adenylate cyclase stimulation along the nephron
(based on the work of Morel, De Rouffignac and collaborators),
in rat and rabbit [32]. The nature of the response is a charac-
teristic of each cell type and is common to each hormone; it
may become evident only in the "hormone deprived" animal
[11]. Net effects may differ between peptides because different
cells exhibit different responses and receptor affinity varies [10].
The renal effects of newer peptides, such as vasoactive intesti-
nal polypeptide (VIP) and calcitonin gene-related peptide
(CGRP), which also stimulate adenylate cyclase [33, 34], can be
studied in this way. For established hormones, like AVP, this
also raises the possibility of pleiotropic renal effects, such as,
increased water and sodium reabsorption [11]. However, the
problem with many gut-brain peptides is that their cell mecha-
nism(s) of action is not well defined; the only clues we have
come from studies in gut-related tissues, for example, pancreas
and salivary gland [35]. Though obviously each peptide may not
act through an exclusive second messenger system, it is worth
broadly classifying and discussing them in terms of their pre-
dominant, or characteristic cell mechanism—cAMP stimulation
versus antagonism and/or phosphoinositol breakdown.
Table 1 lists some of the characteristics of those neuropep-
tides with established or potential renal effects; up to now the
renal actions of only a few neuropeptides have been reported.
Where possible, each peptide will be considered in the se-
quence: nature, distribution, organ and cellular effects (includ-
ing trophic) and likely mechanism(s) of action. What is known
of their effects on renal cell growth will be discussed separately.
Renal function
Peptides that stimulate cAMP
VIP and related peptides. These include growth hormone
releasing factor, glucagon, secretin, gastric inhibitory peptide
(GIP), peptide histidine isoleucine (PHI) and peptide histidine
methionine (PHM); the last two being most closely related to
VIP and derived from the 170 amino acid (aa) precursor,
pre-pro-VIP [36]. Since these peptides have extensive amino
acid sequence homology, their effects may be qualitatively
similar, or even competitive. They all seem to act via stimula-
tion of membrane bound adenylate cyclase [37] and can also
bind calmodulin [38], which may account for their marked
vasorelaxant property [39].
(i) VIP, PHI and PHM. VIP was isolated originally from
porcine duodenum and later found throughout the small and
large bowel [40]. At first it was thought to be confined to specific
endocrine cells, but was soon found in nerve terminals and
neurons of the peripheral and central nervous systems [41]. It is
now believed to be an important peptide neurotransmitter
involved in noncholinergic-nonadrenergic control of vasomotor
tone in exocrine tissue (such as, salivary gland), where it is
co-released with the classical neurotransmitter acetylcholine
[13], and in some vascular beds [42, 43]. Though VIP is not
considered a true circulating hormone, there are reports of
raised plasma levels in the dog after an oral osmotic load [44]
and i.v. administration of cholinesterase inhibitors [45]. In
terms of growth and development, raised circulating levels are
found in the normal fetus and neonate, where its vasodilating
and attendant metabolic effects might be important [46, 47].
The liver and kidney are the prime sites of metabolism for
blood borne VIP; there is significant extraction of VIP by the
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Fig. 2. Composite scheme of peptide stimulation of adenylate cyclase along the nephron, based on references 10, 11, 53, 60, 61, 62, 84, 85, 101,
294, 299. Abbreviations are: ISO, isoproterenol; AVP, arginine vasopressin; PTH, parathormone; CAL, calcitonin; GLU, glucagon; SECR,
secretin; VIP, vasoactive intestinal polypeptide. Symbols are: 1-, stimulation; (-I-), uncertain (species difference/overlap); —, no stimulation;?, not
known (information not available).
liver, and varying reports of raised systemic blood levels in
patients with liver cirrhosis, severe cardiac failure (and shock)
endotoxic shock, inflammatory and ischemic bowel disease
[48—50]. At one point, VIP was even mooted to be the vasoac-
tive factor causing the hepato-renal syndrome, or as the initia-
tor in hepatic edema [51].
Its effects on renal function, at least when infused i.v., seem
mainly due to its potent cardiovascular actions [52]. However,
as with many of these neuropeptides, there may be considerable
species variation in distribution and response [53]. There is now
good evidence that systemically, or locally, infused VIP causes
natriuresis in rabbit and rat [54—56]. VIP-like immunoreactivity
in renal nerve terminals is well documented in the rat, in
relation to blood vessels and the juxtaglomerular apparatus
[57—59], but there is no clear evidence in relation to tubules.
Whether neural VIP exists in the rabbit kidney is not known,
but VIP-specific adenylate cyclase has been found, especially in
the glomerulus, early distal tubule and medullary collecting
duct [33, 60, 53]; there seems to be a similar pattern in rat and
dog kidney [61, 53]. In the rat, this corresponds to the distri-
bution of high-affinity VIP binding sites [62] and in the dog
intra-arterial infusion of dibutyrl cAMP mimics many of VIP's
renal effects [44]. No VIP-like immunoreactivity has been found
in human kidney [63], but VIP-sensitive adenylate cyclase is
present [64]. However, in man the systemic hemodynamic
effects are so pronounced that it is not possible to determine
any specific renal effect [52]. Because of its hemodynamic
effects, suggested roles for VIP have been the regulation of
intrarenal blood flow and renin release [45]; although VIP can
stimulate renin release independently of any vascular effect
[65]. An early study in dogs showed that VIP was not respon-
sible for the rise in renin during sodium depletion, or following
hemorrhage [45]. Studies in rats using i.v. bolus injections of
several neuropeptides together with the microsphere technique
have shown that the homologous peptide PHI lacks the more
general hemodynamic effects of VIP, though both peptides
failed to alter renal blood flow [39].
In renal tissue culture preparations, VIP has can stimulate
adenylate cyclase and transepithelial ion (Cl) transport of
MDCK cells (distal tubule line from dog kidney), but unlike rat
and rabbit enterocytes, no VIP binding sites have been found
[66, 67]. Chloride secretion in the shark rectal gland is also
cAMP-dependent and VIP may be its prime regulator [68]. In
small bowel mucosa, T84 cell tissue culture (colon-derived) and
shark rectal gland, VIP increases the chloride conductance of
the apical cell membrane and may also stimulate a basolateral
Na-2Cl-K cotransporter (at least, indirectly) and associated
potassium conductance (re-cycling) [69] (Fig. 3), that is, of
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Table 1. Summary of distribution and known renal effects of several candidate" renal neuropeptides
Distribution
Peptide (aa)
(immunoreactivity/binding sitesa) Renal effects
Vascular Direct Ref.Vasculature Kidney Circulation
Gut-brain
Bombesin (14) — — — + + + 142, 144
CCK8 (8) — — + + + 128, 133
CGRP (36) + (+) (+) + ÷ 108, 110
Gastrin (17/33) — — — + + 128
Glucagon (29) + — + + + + 84, 83
Insulin (51) — — + + — + 166, 246
NPY (36) + + + — + + 201, 205
Neurotensin (13) (—' + + + + 177, 178
Enkephalins (5) — — + + + + 12, 121
Secretin (27) + — + + ÷ + 101, 96
Somatostatin (14/28) — ÷ + + ÷ + 23, 160
Substance P (11) — + — ? + + 185, 187
VIP (28) + + + — + + 53 58
Neuro-
ANGII (8) + + + + + + 268, 269
ANP (23/28) + — + + + + 271, 272
AVP(9) + — + + ÷ + 273
Bradykinin (9) + — + + + + 189, 274
Endothelin (21) + + ? + 234, 239
Abbreviations are: aa, amino acid number; CCK8, cholecystokinin octapeptide; CGRP, calcitonin gene-related peptide; NPY, neuropeptide Y;
VIP, vasoactive intestinal polypeptide; ANGLI, angiotensin II; ANP, atrial natriuretic peptide; AVP, arginine vasopressin. Symbols are: +, present
and/or effect; —, not present and/or no effect; (+), uncertain; ?, not known or unreported.
a Specific binding sites and/or characterized receptors
b Report of renal nerve immunoreactivity adjacent to juxtaglomerular apparatus—see [307]
Fig. 3. Enterocyte cell model showing ion
transporters and postulated channels, based on
the work of Dharmsathaphorn et al [67, 69]. The
kidney thick ascending limb can be considered to
be of opposite polarity, except for the Na-K-
ATPase pump. Of some interest, in the context
of potassium channel opening, is that in vivo
microperfusion of cortical loops of Henle during
i.v. VIP administration in rats, causes a >50%
reduction in loop potassium reabsorption (JK)
(J Physiol (abst) 420:141 P, 1989, used with
permission).
the effect of glucagon on mammalian late distal tubule and
cortical collecting duct [74]. In pancreatic acinar tissue there is
also a relationship between bicarbonate and chloride secretion
[75]. In the medullary collecting duct a similar effect on baso-
lateral chloride conductance should increase proton secretion
[76]; in rabbit and man VIP infusion was associated with a fall
in urine pH, consistent with such an effect [54]. Thus VIP could
be involved in urine acidification, but as mentioned above, quite
how this effect ties in with the reported increases in sodium
excretion (in the apparent absence of changes in filtered load) is
Apical Basolateral
K
Na *
2 Cl -
opposite cell polarity to the thick ascending limb (TAL) [701,
except for the Na-K-ATPase pump. From this cell model VIP
might be expected to increase sodium reabsorption in the TAL,
as does glucagon [711, at odds with the loop natriuretic effect
observed in the rat [72, Unwin unpublished observations].
VIP has also been shown to stimulate bicarbonate secretion
in turtle urinary bladder (a model for the mammalian cortical
collecting duct) [73], perhaps through changes in apical Cl/
HCO3 exchange in type B intercalated cells, secondary to an
increase in basolateral chloride conductance; this is similar to
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unclear. Like PTH and adrenal steroids, VIP-like peptides may
contribute to acid-base homeostasis; but differing membrane
polarity and grouping of these postulated ion transporters
makes extrapolation from one tissue to another very difficult—
direct studies are needed.
The questions remain: Does VIP have any physiological
action on the kidney, and if so, is it secondary to a local
vascular effect, or a direct tubule effect? A circulating hormonal
effect seems unlikely, but a peptidergic action, more likely on
the intrarenal blood vessels than tubules, does not. Interactions
with other regulatory peptides may be important: VIP-con-
taining nerves exist in the rat adrenal, medulla and cortex [77];
VIP stimulates adrenal corticosterone and aldosterone secre-
tion [78], and pituitary release of the antinatriuretic prolactin [9,
79]. As an example of the danger of species extrapolation, in the
rat, VIP suppresses ANP levels [80], whereas in man it has the
opposite effect [81].
(ii) Glucagon. Glucagon is present in A-cells of the pancreas
and gut [821; glucagon-like immunoreactivity has also been
found in brain, particularly around the hypothalamus [15]. Its
natriuretic and renal vasodilating (pre-glomerular) effects are
well known [83]. Like VIP, glucagon stimulates renal tubule
adenylate cyclase, but there is species variation: in the rabbit
there is no significant stimulation of tubule adenylate cyclase,
but in the rat there is marked stimulation along the cortical thick
ascending limb and collecting duct [32, 84]. Glucagon also
inhibits proximal tubule (where there is no sensitive adenylate
cyclase) sodium reabsorption in the rat, but the cell mechanism
is unknown [10]. There are no reports of glucagon-like immu-
noreactivity in the kidney, but unlike VIP, glucagon is a true
circulating hormone. Glucagon-induced increases in glomerular
filtration rate mask an effect of increased NaCI transport in the
TAL, and a possible role in sodium recycling and urine con-
centration [851. A recent review by Paillard and Bichara [74]
discusses the effect of glucagon on nephron bicarbonate trans-
port and as a possible factor in hormonal regulation of acid-base
balance (cf. VIP above).
The potential role of glucagon in mediating postprandial
changes in renal function (increased renal blood flow and
sodium excretion) has already been mentioned and remains the
subject of considerable interest and some controversy [161.
Glucagon levels rise after food and increase following treatment
with atropine, but a clear and consistent relationship to in-
creased renal blood flow is still lacking [17]. Some years ago,
glucagon release was thought to be the effector limb of the
postulated gastrointestinal or portal sodium monitor [19]. Even
now, transduction through hepatic portal chemoreceptors may
involve small unmyelinated afferent nerve fibers activated by
depolarization [86]; except for the opioids, most gut peptides
appear to depolarize the cell membranes of excitable tissue [87,
881 and so could be important stimuli. Of some therapeutic
interest is the observation that when glucagon and insulin are
administered together in patients with decompensated cirrho-
sis, prothrombin time (an index of hepatic function) improved
and sodium and water excretion increased [891.
(iii) Secretin. Secretin is present in endocrine cells (S-cells) of
the small bowel, with highest concentrations in the duodenum
[90]. The precise structure of human secretin is unknown, but
evidence suggests a single molecular form almost identical with
porcine secretin [91]. Early reports of a secretin-like peptide in
pig brain [92] may have been identification of what is now PHI
[93], although secretin can selectively stimulate hypothalamic
cAMP [94]. Like VIP and glucagon, tissue receptors for secre-
tin have been found outside the gut, specifically in the cardio-
vascular system [95]; a predominantly secretinergic system may
exist in rat heart and kidney [96]. A circulating effect seems
unlikely, in spite of the small postprandial rise [91]. Some have
suggested a role as a "stress hormone" ([97] cf. AVP). The
pharmacological actions of secretin include variable increases
in renal perfusion, urine flow, sodium excretion and bicarbon-
aturia in man ([98, 99] cf. glucagon). Many are controversial and
result from administration of high doses, more than 1 clinical
unit (CU) per kilogram. Secretin's diuretic and natriuretic effect
may also be due to changes in renal interstitial pressure [100].
However, a recent study in the rat, which did not record
glomerular filtration rate, reported an antidiuretic and antina-
triuretic effect (cf. glucagon and calcitonin effects in the TAL),
with a net excretion profile similar to VIP, rather than glucagon
[101].
Calcitonin gene-related peptide. CGRP, a 37 aa peptide is a
chronotropic, inotropic and potent arterial (EDRF and cAMP-
dependent) vasodilator [102—104]. It is found in the circulation
and in perivascular nerve terminals and ganglia of many tissues,
except kidney [105, 106]. Like substance P it is probably an
afferent neurotransmitter and both these peptides are found in
sensory nerves of the urinary tract [107]. Apart from its renal
vasodilating effect [108] and consequent renin stimulation [109],
CGRP may interact with renal calcitonin receptors [110]; there
is no evidence of specific renal CGRP receptors'. Depending on
dose, and central versus peripheral administration, it may
reduce renal and mesenteric blood flow [111]. A specific effect
on renal function seems unlikely, but a recently discovered
antagonist fragment could be used to clarify this [112].
Peptides that inhibit cAMP and/or stimulate inositol lipid
breakdown
Opioids. All opioids share the N-terminal sequence Tyr-
Gly-Gly-Phe; they differ between C-terminal leucine and methi-
onine and may be C-terminally extended (such as, beta-endor-
phin), and come from the precursor pro-opiomelanocortin
[113]. Met- and leu-enkephalin bind to mu and delta receptors,
respectively; morphine is also a mu agonist and naloxone a mu
antagonist. There is a complex receptor subtype composed of
kappa-delta-mu, to which both endogenous peptides bind.
Met-enkephalin is localized with oxytocin in the supra-optic
and paraventricular nuclei projecting to the posterior pituitary
[114].
Beta-endorphin, melanocyte stimulating hormones and the
smaller enkephalins can be measured as circulating hormones
[12, 115, 116]. In man, i.v. administration of a synthetic
met-enkephalin analogue inhibits vasopressin release in re-
sponse to osmotic stimuli [117] and is diuretic; but in the dog,
met-enkephalin and its synthetic analogue have opposite effects
on renal function—native met-enkephalin being antidiuretic and
antinatriuretic (independent of renal nerves) [118]. Immunore-
active alpha- endorphin and met-enkephalin have been found in
See reference 300.
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cultured kidney cells [1191 and binding of beta-endorphin in-
creases after saline loading and water deprivation in rats [1201,
but the significance of this is not known. Similarly, kappa
binding sites have been reported in the rat renal cortex [121] and
kappa agonists are known to be antinatriuretic [122].
Opioids are linked somehow with renal nerve activity (al-
though opioid-containing nerve terminals have not been identi-
fied in the kidney) [121 and may have a dual role in blood
pressure regulation [123, 1141: contralateral natriuresis follow-
ing unilateral nephrectomy is blocked by naloxone and/or
hypophysectomy [124]; the renin response (increase) to renal
nerve stimulation is inhibited by leu-enkephalin [1251. How-
ever, no definitive statement can be made about the renal and
cardiovascular effects of these peptides. It seems that their
cellular mechanism of action may involve cAMP stimulation
[120], direct inhibition, and even phospholipid breakdown.
Since met-enkephalin can actively bind to renal All receptors
[126], that raises a number of "renal" possibilities. Finally,
beta-endorphin may have a trophic role as a mesangial cell
co-mitogen [127].
Cholecystokinin (CCK) and gastrin. Various forms of these
peptides are released after a meal [128, 129]. They share the
biologically active C-terminal tetrapeptide sequence -Trp-Met-
Asp-Phe-NH2, but only CCK, in the form of its octapeptide, is
considered a true neuropeptide, although gastrin as G 17 has
been found in the posterior pituitary gland [130, 131].
The biological activity of CCK depends on sulphation of its
27 tyrosine residue, and the unsulphated form can function as a
partial agonist or blocker [132]. Though early reports suggested
that either CCK or gastrin may increase renal blood flow
(compare with glucagon and secretin), later studies failed to
show any effect, except at high doses and supraphysiological
plasma concentrations [128]. However, recent experiments in
the anesthetized rat and conscious rabbit suggest a direct tubule
natriuretic effect of CCK8, possibly along the loop of Henle [72,
133]. Renal hyperemia in the rat model of portal hypertension
(postulated cause is increased blood levels of unmetabolized
vasoactive gut peptides) is not associated with raised arterial
blood levels of any gut derived peptide, including gastrin and
CCK [134]. In CRF patients on dialysis, levels of CCK and
gastrin are increased, as is the response to a standard meal
[135]. This is also true of secretin, somatostatin, GIP (the raised
GIP may depress gastrin) and glucagon [136], but there is no
correlation with gastrointestinal disturbances, and the implica-
tions for renal dysfunction remain unexplored.
CCK's cellular mechanism of action (based on studies in
pancreatic acinar cells), like bombesin, seems to depend on
increases in cytosolic calcium [137], which may in turn depend
on a specific increase in Ca2 influx (via a channel) [35], or
intracellular release through inositol lipid metabolism [138].
Inhibition of proximal tubule sodium reabsorption by PTH may
depend on a rise in intracellular calcium and reduced apical
membrane permeability to sodium [101; although speculative,
CCK8 could act through a similar mechanism [35, 138, 128]. In
addition, stimulation of PKC antagonizes cAMP generation,
which, at least in the rabbit cortical collecting duct, can inhibit
electrolyte transport [139]. Moreover gastrin can stimulate
Na-H exchange in pancreatic acini [140]. However, as
discussed under VIP, drawing parallels between effects on
comparable studies in renal epithelia. In sum, CCK and gastrin
have potential, but are probably not important regulators of
renal function.
Bo,nbesin and gastrin releasing peptide (GRP). Bombesin
was isolated first from amphibian skin [141] and shown to be
vasoconstrictive [142]. Bombesin and GRP, one 14 aa in length
and the other 27 (in man), have been co-localized throughout
the nervous system. Like CCK they both depress appetite when
given centrally or peripherally, but this effect may not be
specific [15]. Centrally administered bombesin stimulates
adrenalin release from the adrenal medulla and causes 'gener-
alized arousal", but whether it can act locally to enhance
sympathetic activity is unclear—bombesin has been implicated
in body thermoregulation through sympathetic efferent activity
in brown fat [143]. An early study in anesthetized dogs showed
effects compatible with noradrenergic stimulation: afferent re-
nal arteriole vasoconstriction and increased renin release [144].
Like CCK, its effects may depend on changes in intracellular
calcium levels (mobilization) through phosphoinositol metabo-
lism; a recent study in the isolated perfused rabbit cortical
collecting duct found inhibition of AVP-induced water perme-
ability by bombesin, perhaps through PKC activation [145].
Like VIP, bombesin has also been found in shark rectal gland
and to antagonize VIP-induced chloride secretion, perhaps, as
indicated above (see CCK), by inhibiting cAMP generation
[146]. However, a trophic role may be equally important:
bombesin probably has a trophic action in small cell carcinoma
of the lung [147] and stimulates fibroblasts via PKC [148], but its
effect on mesangial cell proliferation (see later) is modest. There
are no reports of bombesin, or bombesin receptors, in the
kidney.
Finally, as with competitive antagonist analogues of LHRF,
altering (replacing) the histidine of bombe sin produces compet-
itive blockers [149]. In order to understand the significance of
the renal effects of bombesin and other neuropeptides, peptide
antagonists are needed. Their development and use will un-
doubtedly improve our understanding of peptide physiology.
Sornatostatin. Originally extracted from the hypothalamus,
there are two circulating forms of this paninhibitory (pros-
taglandins and opioids excepted) peptide: S-14 and S-28. Its
distribution and variety of actions have been summarized in 2
recent reviews [150, 151].
The liver and kidney can synthesize small quantities of a
somatostatin-like peptide [152], and somatostatin-like immuno-
reactivity has been found in rat glomeruli [23]; amino acid
superfusion of these glomeruli releases a somatostatin-like
substance [153]. Specific binding sites have also been found in
the rabbit renal cortex and medulla [154], and adrenal cortex
[1551. Somatostatin is vasoactive: i.v. infusion reduces splanch-
nic blood flow and causes a transient pressor response in man
[151], reduces renal vascular resistance in the cat [156], but
increases it in the dog [157]. Plasma somatostatin levels are high
in cirrhosis and uremia, but with no obvious effect on renal
function [135, 1581. Yet i.v. infusion of somatostatin in man
decreases urine flow rate, increases urine osmolality and re-
duces free water clearance without changes in plasma AVP
concentration (creatinine clearance also fell in this study) [159];
decreases in renal perfusion in man have been shown [160]. In
contrast, large doses of S-l4 infused i.v. and directly into the
exocrine tissue and kidney may not be valid—there is a need for renal artery of anesthetized and conscious dogs produce diure-
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sis and increase free water clearance, perhaps by direct antag-
onism of AVP [161, 162], although there is no obvious homol-
ogy between AVP and somatostatin (even cyclic S 14).
Somatostatin inhibition of AVP action is more likely to be due
to inhibition of cAMP [163, 164]: it inhibits adenylate cyclase in
LLCPK1 cell cultures, but has no effect on AVP binding [165].
Its mechanism of action seems to depend, in part, on membrane
depolarization and reduced calcium influx [88, 138].
An unusual property is somatostatin's stimulation of gluco-
neogenesis in renal cortical slices by an alpha1-dependent and
Ca-dependent mechanism (for example, inhibition by insulin
[166]). Somatostatin also increases 45Ca uptake in renal cortical
slices [ISO]. Because of the tight coupling between renal am-
moniagenesis and gluconeogenesis, this effect could be impor-
tant in renal adaptation to acidosis [167].
As in the gut, somatostatin may have a paracrine role, but
quite what this is, and its relationship to water homeostasis,
remains to be discovered. As suggested by Kurokawa et al [23],
its presence in glomeruli may regulate local hormone produc-
tion such as, prostaglandins and angiotensin II (it can also
inhibit diuretic-induced renin release [1681). It may be impor-
tant in renal growth; somatostatin has been shown recently to
inhibit the growth-related somatomedin C accumulation in
kidney seen in insulin-dependent diabetes and following unilat-
eral nephrectomy [169].
Neurotensin (NT). The NT-related peptide neuromedin N is
found in rat kidney, but NT is not [170]; the former's function
is unknown. NT is a putative neurotransmitter and circulating
hormone [171]. NT and dopamine coexist in the hypothalamus
and NT is found in the anterior pituitary [172, 173]. but its
function is again unknown.
Plasma levels are high in renal failure, but the kidney is an
important metabolic, rather than excretory, site for this peptide
[174, 175]. Measured basal circulating NT is composed largely
of N-terminal fragments, but since the C-terminal end is bio-
logically active, this means either an unrecognized action of
circulating N-terminal NT, or a local effect of intact NT. NT (or
neuromedin N, see above) binding sites have been found in rat
renal cortex [176, 177], but even large doses of infused NT
appear to have little effect (including blood pressure) on renal
function in this species [129]. By contrast, NT has been shown
to produce antinatriuresis in conscious rabbits [178], but phys-
iological plasma concentrations have only a weak effect in man
[179]. A significant influence on renal function and sodium
balance seems unlikely.
Substance P (SP) and related neurokinins. SP was the first
gut-brain peptide to be identified and was found originally in the
hypothalamus [180]. SP and neurokinin A (NKA or substance
K; extended SP) are metabolized extensively by kidney en-
dopeptidases [181, 182] (compare with CCK and opiates).
Circulating SP and NT are also hydrolyzed by angiotensin
converting enzyme (ACE), and their levels may increase after
treatment with ACE inhibitors [183].
SP has been found in perivascular nerve fibers of several
species, but as in other tissues, these are probably sensory
afferents rather than vasomotor efferents [21, 176, 184—186].
Studies of SP infusion report variable renal vasodilation, diure-
sis and natriuresis, depending on the route of administration
[187—189]. It has also been shown to stimulate hypertrophy of
the adrenal zona glomerulosa and release of aldosterone [190].
Its likely cellular mechanism of action is not known, but as a
pancreatic (and salivary) secretagogue, like CCK and bombe-
sin, it probably involves phosophoinositol metabolism and
raised intracellular calcium [138].
Little is known of the physiological stimuli to SP release,
although plasma concentrations have been reported to rise on
standing and fall during sodium deprivation [191]. Once again, it
is difficult to postulate a role for SP in the control of renal
function; although it might be involved in the afferent limb of
reno-renal reflexes (compare with CGRP [192]). The renal
effects of NKA, NKB and NPK have not been studied; NKA
depresses salt appetite when given centrally [193].
Of potential significance, now that plasma and urine cGMP
levels are being used as indices of ANP activity [194], is that SP
also stimulates renal guanylate cyclase [195].
Neuropeptide Y (NPY) and related peptides. (i) NPY and
homologues. NPY is a 36 aa peptide structurally related to
pancreatic polypeptide (PP) and peptide YY (PYY has 25 aa
homology with NPY and 18 aa homology with PP), present in
brain and peripheral nerves; it appears to be exclusively neu-
ronal [196]. Unlike NPY, PYY is not a neuropeptide, but like
PP. it is found in gut and circulating levels rise after food [14,
15]. Like NPY it is a powerful vasoconstrictor [196]. All three
peptides are satiety factors, and in particular, central adminis-
tration of NPY and PYY increase water intake [15].
Levels of circulating NPY increase following hypotension,
exercise [198] and in cardiac failure [199], situations in which
sympathetic nerve activity is high. Neural NPY seems to be
sympathetic and noradrenergic: tissue levels, including kidney,
are depleted after treatment with reserpine or 6-OH-dopamine,
probably due to loss of alpha2 feedback inhibition [200]. Thus
the kidney seems to contain a mixture of adrenergic and
nonadrenergic fibers, and NPY may be an important sympa-
thetic neurotransmitter. Binding sites for NPY have been found
in rabbit proximal tubule and renal vascular smooth muscle,
and a role in sodium reabsorption has been postulated [201]. In
the isolated perfused rat kidney NPY produces natriuresis
[202], but no NPY binding sites have been found in rat, guinea
pig or man (sparse) [203, 204, 59]. NPY-containing nerve
terminals have been shown along the renal arteries and adjacent
to the juxtaglomerular apparatus of rats, man, monkey, mouse,
hamster and guinea pig [205, 206, 59].
NPY inhibits renin release in the isolated perfused rat kidney
and causes intense vasoconstriction: inhibition of renin does
not appear to depend on cell calcium fluxes, or stimulation of
the macula densa (hydronephrotic kidneys), but is prevented by
pretreatment with pertussis toxin [207]. Thus its effect on renal
blood vessels and renin release probably involves inhibition of
adenylate cyclase via G protein, perhaps through alpha2-
adrenergic stimulation (NPY inhibition of AVP action in rat
cortical collecting duct) [208, 209]. NPY also inhibits cAMP
generation in cultured bone [210] and erythroleukemia cells
[210], but some of is effects may also be secondary to calcium-
dependent prostaglandin release [211, 212]. Similar mechanisms
may explain NPY's antisecretory effect in intestinal epithelia
[213—216], where it inhibits VIP-stimulated chloride secretion,
but it also blocks substance P stimulated secretion, which is
cAMP independent [217]. VIP and NPY may also interact in
renal blood vessels and tubules [59], but note that for both
peptides, a natriuretic effect has been described; however,
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either one might have a peptidergic role in, for example, neural
control of distal bicarbonate transport [2181? A recent study of
NPY infusion in conscious primates reported intense renal
vasoconstriction associated with reduced sodium excretion and
no change in renin secretion [219].
As indicated, NPY has marked cardiovascular effects: it
increases peripheral vascular resistance and blood pressure,
and reduces cardiac output [220, 102]. In two rat models of
hypertension, coarctation (clipped aorta above renal arteries)
and renovascular (1 or 2 clipped renal arteries), levels of NPY
and catecholamines are reduced in most tissues and blood
vessels, including kidney [221, 222]. Like chemical sympathec-
tomy, these changes have been attributed to neuronal depletion
secondary to increased nerve activity [223, 198], and has led to
the suggestion that NPY might be involved in neurogenic
control of blood pressure.
More recently, NPY binding sites have been found in the rat
adrenal cortex (NPY is present in the adrenal medulla [224]) and
NPY could modulate aldosterone secretion peripherally and
centrally [225], potentiating the response to known agonists
[226]. Clearly NPY has considerable potential for influencing
many aspects of renal function.
(ii) PP. Though PP was at first thought to be a neuropeptide,
true PP is confined to the pancreatic islet cells and part of the
duodenum [2271—what was thought originally to be brain PP
was probably NPY. In view of its apparent stimulation of small
bowel water and electrolyte reabsorption [228], and what may
be adaptively high levels in patients with ileostomies [229], its
potential effect on renal function was studied early on, but
nothing was found [230].
Endothelin. Though not strictly a gut-brain peptide, endothe-
lin is a 21 aa neuropeptide produced by endothelium [2311; it is
included here because of its recent discovery and potential
importance. It is an intense renal vasoconstrictor, some 10
times more potent than NPY [232] and specific binding sites are
found in most vascular beds [233]. There are receptors in the
kidney, mainly glomeruli and inner medulla (collecting ducts
and loops of Henle), a localization similar to angiotensin II and
ANP [234]. Their distribution does not coincide exclusively
with the intra-renal vasculature and endothelin may have direct
effects on the renal tubule [235, 2361. At stressfully high
infusion rates, plasma renin activity and AVP increase [237];
ANP levels rise during low dose infusion and ANP is also
released from isolated atria in vitro [2381. It has been implicated
in the pathogenic response to renal injury—"shock" kidney—
and may be important in mesangial cell proliferation (see later)
[239—242].
Its cell mechanism of action is uncertain; in vitro renin
inhibition is independent of external calcium and is not blocked
by dihydropyridine calcium antagonists [243]. However, its
vasoconstrictive effect appears to be calcium channel-depen-
dent [234].
Insulin. Unlike other neuropeptides, brain insulin comes
from the peripheral circulation [244]. Insulin's antinatriuretic
effect is well known, although not always reproducible [245]. Its
effect on the renal proximal tubule was reviewed recently [166].
There are reports of insulin receptors along the rabbit nephron,
especially along the thick ascending limb and distal convoluted
tubule, which are likely to be of functional and metabolic
significance [246]. The antinatriuretic effect of insulin has been
observed within the physiological range of plasma concentra-
tions and can be dissociated from its effects on glucose and
amino acid transport [247]. Work in the isolated frog skin has
shown that insulin acts from the cell basolateral membrane to
increase apical membrane sodium permeability through stimu-
lation of protein kinase C [2481 (Paradoxically, an early study
reported that insulin inhibits hormone-stimulated protein kinase
systems [249]). An in vitro study in the isolated perfused rabbit
proximal convoluted tubule showed direct stimulation of vol-
ume reabsorption when physiological concentrations of insulin
were added to the bath, but not the lumen [250]. This is
compatible with evidence of insulin-enhanced Na-H ex-
change and stimulation of Na-K-ATPase [166], but not with
the reduced sodium and water reabsorption seen during in vivo
micropuncture [251]. From this early micropuncture study,
reduced net sodium excretion suggests a more distal site of
action. Moreover, another, more recent micropuncture study
did not find any effect of insulin on chloride and water reab-
sorption in the proximal tubule, but did find reduced distal
delivery of chloride [252], showing enhanced loop of Henle
reabsorption, similar to glucagon and calcitonin [11]. That
insulin may have a physiological effect on renal sodium secre-
tion is also suggested by a study on the hormonal response to
dietary sodium restriction in man, in which a low sodium diet
was associated with an enhanced insulin response to feeding
[229].
Finally, the likely interaction between insulin and its related
growth factors [253] needs to be clarified [254].
Table 2 details some of the net renal effects of neuropeptides
listed in Table 1.
Mesangial cell growth
Table 3 lists the most often used indices of cell growth in
culture. Table 4 summarizes known neuropeptide effects on
mesangial cell mitogenesis and related ion transport mecha-
nisms.
Overview
Much of the pioneering work on cell growth regulation,
including neuropeptide growth factors and signal transduction
mechanisms, has been done on fibroblasts by Rozengurt and
colleagues [255, 256]. Advances in cell culture techniques,
specifically of mesangial cells (MC), have provided a means of
studying the effects of biologically active peptides on renal cell
growth, and of examining some of the mechanisms that may
regulate growth in these cells. Up to now, the growth stimulat-
ing effects of only a few neuropeptides have been studied (Table
4). More work has been on the larger. polypeptide growth
factors [257, 258].
Proliferation results from agonist stimulation of MC growth
cannot be easily categorized: it is not possible to generalize, or
classify growth patterns according to the nature of the stimulus,
such as, vasodilator versus vasoconstrictor. While vasodilators
VIP and bradykinin are potent MC mitogens, and bombesin
(vasoconstrictor) is mildly mitogenic, SP (vasodilator), NPY
(vasoconstrictor) and NT (vasoconstrictor) are not. Of interest
is that while atrial natriuretic peptide (ANP) can inhibit cell
growth, this effect depends on which form of ANP is used:
ANP-23 is inhibitory, but ANP-28 is not. As far as we know,
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Table 2. Summary of neuropeptide (see Table I) effects on renal haemodynamics, renin release, and electrolyte (sodium and water) excretion
Peptide
Renal hemodynamics
Renin
Renal excretion
Sodium Water Ref.GFR RBF RVR FF
Gut-brain
Bombesin — — + (—) + ? 44, 145, 146
CCK8 + + — ? (—) + + 128, 133
CGRP (+) + — + + — — 108, 110, 300, 301
Gastrin ? (+) ? ? ? ? — 128, 302
Glucagon ? (+) + 83
Insulin ? ? ? ? (+) — (—) 166, 303
NPY — — + ? — (+) ? 202, 207, 308
Neurotensin (—) (—) (+) ? (+) — 178
Enkephalins
Secretin
?
(+)
?
(+)
?
?
?
?
?
+
?
(+)" (+)
12, 117, 118, 122
96, 98, 99, 101
Somatostatin (—) (—) 1- ? — (—) (—) 159—163, 308
Substance P (—) (+) ? ? (—) (+) (+) 187—189, 308, 309
VIP (—) (+) (—) ? + (+) (+) 52, 54—56, 308
Neuro-
ANGII (—) — + + — (—) (—) 304
ANP (+) (+) (—) (+) — + + 305
AVP ? ? ? ? — (—) — 304
Bradykinin + + — ? + + + 189
Endothelin — — + 7 — — — 239, 306
Abbreviations are: GFR, glomerular filtration rate; RBF, renal blood flow; RVR, renal vascular resistance; FF, filtration fraction; CCK8,
cholecystokinin octapeptide; CGRP, calcitonin gene-related peptide; NPY, neuropeptide Y; VIP, vasoactive intestinal polypeptide; ANGLI,
angiotensin II; ANP, atrial natriuretic peptide; AVP, arginine vasopressin. Symbols are: +, increase; —, decrease; 7, no effect or unreported; (+)
or (—), variable or inconsistent effect.
Can inhibit AVP action on cortical collecting duct
ID Can stimulate NaCI transport in thick ascending limb
1. Cell (number) counting
2. 3H-thymidine uptake/incorporation
3. (DNA spectrofluorimetry)
4. Change in pH
5. Change in Ca1
6. Change in cAMP production
7. Phosphoinositol lipid turnover
8. Proto-oncogene expression
effects of other neuropeptides, such as cholecystokinin/gasti-in
and opiates on mesangial cell growth have not been studied.
Cell signaling
The molecular mechanism(s) by which these agonists alter
cell function is the subject of intense study [259—261]. A detailed
discussion of all potential transmembrane signaling pathways is
beyond the scope of this review, but, as already mentioned,
there appear to be two main pathways by which these peptides
could alter cell function: (1) activation of guanine nucleotide
binding proteins (G proteins) coupled to cAMP and (2) phos-
phoinositol metabolism and activation of PKC. At present,
there is considerable interest in U protein-cAMP coupling and
transmission of the mitogenic signal [262—264]. Jaffer, Baird and
Abboud [2651 have postulated a direct link between G protein
ribosylation/cAMP generation and MC proliferation. They
found that beta-adrenergic agonists, such as isoproterenol,
which are known to stimulate adenylate cyclase and increase
cAMP, blunt the mitogenic response induced by platelet-de-
rived growth factor (PDGF), serum and other growth factors.
Several of the brain-gut peptides already discussed stimulate
cAMP production, but as shown in Table 4, some promote cell
growth yet increase cAMP [266]. Clearly, the cell signaling
process in this instance is more complex and poorly under-
stood. Of the second pathway, phosphoinositol metabolism and
PKC activation, AVP and bombesin can initiate cell growth
through a PKC-dependent mechanism which does not involve
cAMP in fibroblasts [2551 and, more recently, in MC [266, 267].
Ion translocation—pH and calcium
Of the neuropeptides listed in Table 4, several raise intracel-
lular calcium concentration (Ca1) and increase intracellular pH
(pH1), factors thought to be important in the initial phase of
growth [268]. The importance of changes in calcium fluxes has
been supported by observations that contraction of MCs in-
duced by agonists can be inhibited by calcium entry blockers.
In fact, in MCs, changes in Ca, appear to be uniform (a rapid
and transient increase in Ca1) for most neuropeptides, except
bradykinin. Neuropeptide-induced changes in pH1 have also
been shown: stimulation of Na-H exchange (without C02/
bicarbonate) leading to cytosolic alkalinization. While alter-
ations in Ca1 may explain changes in glomerular filtration rate
through MC contraction, the role of calcium in growth is not
clear, for example, AVP-induced calcium transients can be
dissociated from growth, but seem to be (at least partially)
necessary for bombesin's mitogenic effect. However, in MC,
these Ca and pH1 signals can be temporally dissociated from
the proliferative response, such as, SP [266], where neither
change, and are not primary events in the growth response.
Like the membrane signaling mechanism(s), the significance of
these ionic changes is poorly understood.
Table 3. Commonly used indices of cell growth stimulation in culture
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Table 4. Summary of known effects of neuropeptides on some indices of mesangial cell growth stimulation in culture
[3H]-
thymidine PIP
Peptide incorporation pH4 [Ca2]4 cAMPs turnover References
Brain-gut
Bombesin ++ +09 + 15-3 (—) +++ 266, 285, 288, 289
CCK8 — — — — —
CGRP - - - - -
Gastrin — — — — —
Glucagon — — — +++ — 292
Insulin/IGF-l +++ ++I(—) no change — ++ 253, 293
NPY no change no change no change +++ — 266,285
Neurotensin — — — — .
Enkephalins +++ — — — — 127
Secretin — — — — —
Somatostatin — —05 — (—) — 165, 285, 296
Substance P no change +05 + 15-30 — — 266, 275
VIP +++ — — +++ — 266
Neuro-
Angiotensin II ++/no change +17 +3-5 +++ +++ 276, 283, 286, 287
ANP 23/21 (—) — decrease no change — 267, 278—282
ANP 28 no change — decrease no change — 275, 280
AVP +++ +15 +3-5 ++ +++ 275,277,291
Bradykinin +++ —05 +5-6 +++ +++ 285, 286, 290, 291
Endothelin +++ +25 +5-7 — +++ 241, 242, 295
3H-thymidine (fold increase) represents the maximal proliferative response at 24 or 48 hr pH1 response represents the change in pH1 units in a
HEPES-buffered solution; the absence of C02/HCO3 [Ca2]1 (fold increase) represents the maximal calcium transient; —, not known; (—),
uncertain.
Abbreviations are: CCK8, cholecystokinin octapeptide; CGRP, calcitonin gene-related peptide; NPY, neuropeptide Y; VIP, vasoactive
intestinal polypeptide; ANGLI, angiotensin II; ANP, atrial natriuretic peptide; AVP, arginine vasopressin
Conclusion
Although this review raises many more questions than it
answers, at the very least it provides an imperfect source, or
catalog, of current knowledge on the actual and potential renal
effects of several widely distributed neuropeptides. Some of
these peptides, that is, VIP, NPY, endothelin, and possibly
somatostatin, are clearly worth more study in a renal context.
With the advent of single channel recording and its applica-
tion to renal epithelia, has come an appreciation of molecular
regulatory mechanisms and the need to define them. Whether or
not any of these peptides prove to have significant and physio-
logical effects on renal function, they may provide a means of
explaining and understanding the interactions between these
cell signaling mechanisms (especially when specific blockers
become available), their role in tubule ion transport processes
and normal and abnormal mitogenesis.
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